JP2024538669A5 - - Google Patents

Info

Publication number
JP2024538669A5
JP2024538669A5 JP2024520079A JP2024520079A JP2024538669A5 JP 2024538669 A5 JP2024538669 A5 JP 2024538669A5 JP 2024520079 A JP2024520079 A JP 2024520079A JP 2024520079 A JP2024520079 A JP 2024520079A JP 2024538669 A5 JP2024538669 A5 JP 2024538669A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
seq
amino acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/122556 external-priority patent/WO2023051683A1/zh
Publication of JP2024538669A publication Critical patent/JP2024538669A/ja
Publication of JP2024538669A5 publication Critical patent/JP2024538669A5/ja
Pending legal-status Critical Current

Links

JP2024520079A 2021-09-29 2022-09-29 抗lag3二重特異性抗体、医薬組成物、及び使用 Pending JP2024538669A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111149114 2021-09-29
CN202111149114.9 2021-09-29
PCT/CN2022/122556 WO2023051683A1 (zh) 2021-09-29 2022-09-29 抗lag3双特异性抗体、药物组合物及用途

Publications (2)

Publication Number Publication Date
JP2024538669A JP2024538669A (ja) 2024-10-23
JP2024538669A5 true JP2024538669A5 (https=) 2025-10-07

Family

ID=85770153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024519329A Pending JP2024536881A (ja) 2021-09-29 2022-09-28 抗lag3抗体、医薬組成物、及び使用
JP2024520079A Pending JP2024538669A (ja) 2021-09-29 2022-09-29 抗lag3二重特異性抗体、医薬組成物、及び使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024519329A Pending JP2024536881A (ja) 2021-09-29 2022-09-28 抗lag3抗体、医薬組成物、及び使用

Country Status (11)

Country Link
US (2) US20250042995A1 (https=)
EP (2) EP4410835A4 (https=)
JP (2) JP2024536881A (https=)
KR (2) KR20240083095A (https=)
CN (2) CN115873116B (https=)
AU (2) AU2022355381A1 (https=)
CA (2) CA3233205A1 (https=)
IL (2) IL311738A (https=)
MX (2) MX2024003936A (https=)
WO (2) WO2023051621A1 (https=)
ZA (2) ZA202403273B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
JP2024536881A (ja) * 2021-09-29 2024-10-08 中山康方生物医▲藥▼有限公司 抗lag3抗体、医薬組成物、及び使用
CN117159703B (zh) * 2023-11-02 2024-04-02 正大天晴(广州)医药有限公司 含抗lag-3抗体的药物组合物及其用途
WO2025201450A1 (zh) * 2024-03-27 2025-10-02 康方汇科(上海)生物有限公司 药物组合及用途
CN120919303A (zh) * 2024-05-10 2025-11-11 康方汇科(上海)生物有限公司 药物组合及用途
CN120518768B (zh) * 2025-05-30 2025-12-30 中国人民解放军军事科学院军事医学研究院 抗lag-3的单克隆抗体、抗pd-1与lag-3的双特异性抗体、制备方法及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6595458B2 (ja) * 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗lag−3抗体と抗pd−1抗体との組合せ
HUE057817T2 (hu) * 2014-01-28 2022-06-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek haematológiai malignitások kezelésére
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN106632674B (zh) 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
US11045547B2 (en) * 2015-12-16 2021-06-29 Merck Sharp & Dohme Corp. Anti-LAG3 antibodies and antigen-binding fragments
JP7010854B2 (ja) * 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
SG11201811184UA (en) * 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
EP4516809A3 (en) * 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
WO2018217944A1 (en) * 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
CA3085656A1 (en) * 2017-12-22 2019-06-27 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody pharmaceutical composition and use thereof
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
CA3109999A1 (en) * 2018-08-21 2020-02-27 Abl Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
CN115340606B (zh) * 2019-05-31 2023-12-19 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN112079925B (zh) * 2019-06-13 2025-04-25 上海健信生物医药科技有限公司 靶向lag-3的抗体和双特异性抗体及其用途
WO2021063201A1 (zh) * 2019-09-30 2021-04-08 四川科伦博泰生物医药股份有限公司 抗pd-1抗体及其用途
PH12022551278A1 (en) * 2019-11-25 2023-11-20 Akeso Biopharma Inc Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
CN114901306A (zh) * 2019-12-23 2022-08-12 宏观基因有限公司 用于治疗癌症的疗法
CN113348182B (zh) * 2019-12-30 2022-07-12 上海海路生物技术有限公司 Lag-3抗体及其医药用途
EP4095159A4 (en) * 2020-01-21 2024-03-20 Shanghai Henlius Biotech, Inc. MONOCLONAL ANTI-LAG3 ANTIBODY AND METHOD FOR THE PRODUCTION THEREOF AND ITS USE
CN115073588B (zh) * 2021-03-12 2024-06-18 中山康方生物医药有限公司 提高含有免疫球蛋白Fc片段的药物的安全性的方法
JP2024536881A (ja) * 2021-09-29 2024-10-08 中山康方生物医▲藥▼有限公司 抗lag3抗体、医薬組成物、及び使用

Similar Documents

Publication Publication Date Title
JP2024538669A5 (https=)
JP2022515318A5 (https=)
JP2023504003A5 (https=)
JP2024536881A5 (https=)
JP2021524249A5 (https=)
JP2017519759A5 (https=)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2023539501A5 (https=)
RU2013152164A (ru) Анти-в7-н3-антитело
JP2023516004A5 (https=)
JP2026041845A5 (https=)
JP2024509018A5 (https=)
JP2007515165A5 (https=)
JP2025507817A5 (https=)
JP2023518153A5 (https=)
JP2022545741A5 (https=)
JP2020502233A5 (https=)
JP2025511289A5 (https=)
JP2025511288A5 (https=)
JP2024542192A5 (https=)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2024532836A5 (https=)
JP2023516941A5 (https=)
JP2024525916A5 (https=)